Announcement of Adoption of Subsidized Project for "Development of Basic Technology for Creation of Next-Generation Pharmaceuticals for Personalized Medicine (Manufacturing Technology for Next-Generation Antibody Drugs that Meet International Standards)" i
Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) is pleased to announce that the proposal, "Establishment of innovative nucleic acid drug manufacturing technology for nucleic acid APIs and DDS preparations with a view to large-scale production" was selected as a subsidized project by the Ministry of Economy, Trade and Industry (METI) in the fiscal year 2013.
Bonac is currently promoting the pharmaceutical development of Bonac nucleic acid, and it is essential to establish a production system and DDS formulation technology at a practical level.
With the subsidy project adopted this time, Bonac is determined to promote the establishment of the technology as soon as possible.
Bonac will continue to promote our research and development so that our nucleic acid technology will be a bridge to drug discovery.